TissueLabs is building the platform for creating organs and tissues in the lab.
THE FOUNDERS LETTER
"Every day, over 2 million people around the world wake up in the morning with one single dream. They dream with a phone call from the hospital informing that an organ is available for them. Unfortunately, though, the numbers play against their dreams. In fact, only 3 out of 1,000 people die in a way that allows for organ donation. This means half a billion people should die in order to save those patients in the waiting list.
At TissueLabs, we believe this is insane!
We were born with the mission to produce human organs for transplantation. Bringing together an extremely talented team, guided by six core values - ambition, protagonism, passion, innovation, grit, and teamwork - we are building the platform for creating organs and tissues in the lab.
But something else must be said about us. TissueLabs is not a conventional company. And we do not intend to become one. TissueLabs started as the life project of someone directly affected by the problem. This very personal life project, however, rapidly became the life project of a bunch of truly obstinate professionals. All these people are devoted and focused on our long-term goal - to create the first transplantable bioartificial heart in the world.
Even though we are relentless working towards our big dream, we understand that those patients waiting for a phone call do not only need hearts, but also lungs, livers, kidneys and so many other organs. We wanted to be sure no one would be forgotten and this led to the open innovation mindset that drives TissueLabs. As we mentioned before, we are not a conventional company, neither a conventional biotech company. We did not want our technology confined inside the walls of our own laboratories and only brought to the market after ten, fifteen years. One of our pillars is to bring cutting-edge technology in the field of organ fabrication to the market. Every new development we conceive, we transform it into a commercially available product. This allows the whole scientific community to use our platform to create a series of different organs and tissues.
TissueLabs is unconventional and will continually make ambitious bets on new technologies that support organ fabrication. We believe that in the future, treating a disease will be like changing a broken light bulb. TissueLabs will play a key role to make it happen, paving a future where organ failure won’t necessarily mean a death sentence."
Gabriel Liguori, MD, PhD
CEO at TissueLabs
Emerson Moretto, MSc
CTO at TissueLabs
Eduardo Zylberstajn, PhD
Strategy at TissueLabs